Security: Series B Preferred & Debt
Location: Malvern, PA

President & CEO: Shawn Patrick O'Brien
CFO: Michael Pagnotta

New Investors: Highland Capital Management
Existing Investors: Thomas, McNerney & Partners, Investor Growth Capital, Morgan Stanley Venture Partners, Oxford BioSciences Partners

Board of Directors: Doug Fambrough, Brian Gallagher, Nathan Hukill, Fazle Husain, Liza Page Nelson, Shawn Patrick O'Brien, Brett Pope, James Thomas

- Specialty biopharmaceutical company with commercial-stage product Myobloc® (Botulinum Toxin Type B) is indicated for patients with cervical dystonia.

- Lead investor is a SEC-registered investment adviser specializing in credit and alternative investment currently managing over $30 billion in leveraged loans, high yield bonds, structured products and other assets for banks, insurance companies, pension plans, foundations, and high net worth individuals.